Omniab (NASDAQ: OABI) reported Q2 2023 earnings per share (EPS) of -$0.15, up 25% year over year. Total Omniab earnings for the quarter were -$14.73 million. In the same quarter last year, Omniab's earnings per share (EPS) was -$0.12.
As of Q3 2023, Omniab's earnings has grown year over year. Omniab's earnings in the past year totalled -$26.60 million.
What was OABI's revenue last quarter?
Omniab (NASDAQ: OABI) reported Q2 2023 revenue of $6.95 million up 3.51% year over year. In the same quarter last year, Omniab's revenue was $7.20 million.
What was OABI's revenue growth in the past year?
As of Q3 2023, Omniab's revenue has grown 72.28% year over year. This is 27.22 percentage points lower than the US Biotechnology industry revenue growth rate of 99.5%. Omniab's revenue in the past year totalled $66.12 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.